Symbiotec Pharmalab IPO
Symbiotec Pharmalab IPO is a mainboard IPO raising ₹1,757 Cr at ₹938 – ₹988 a share. It listed on 1 Sept 2026 at ₹988, 0.0% against its issue price of ₹988, and trades at ₹1,139 today (+15.3% since issue). It was subscribed 71× in total.
71.3 times more demand than shares on offer
populated partly populated we hold nothing here — the tab says why
Where your money goes
Only the fresh issue reaches the company. The offer for sale is existing shareholders selling their own stock — that money goes to them, not the business.
92% of this issue is existing shareholders cashing out. Only ₹150 Cr reaches the business.
A red herring prospectus is filed before the price is fixed, so it states share counts rather than rupee amounts. stated in prospectus. Checked: exchange issue size Rs1757 Cr vs derived Rs1757 Cr (0.0% apart).
What the fresh money funds
The stated uses of the net proceeds, from the prospectus’s Objects of the Issue table. Only the fresh issue funds these — the offer-for-sale money goes to the selling shareholders above.
As stated in the prospectus. “General corporate purposes” is the part with no committed use; SEBI caps it at 25% of the issue.
The price they’re asking
From the prospectus’s own “Basis for Issue Price” — the issuer’s earnings multiple against the peers it chose to compare itself with.
Priced 43% below the median multiple of the peers the issuer itself names.
| Listed peer (issuer’s choice) | P/E | RoNW | EPS |
|---|---|---|---|
| Concord Biotech Limited | 61.07× | 14% | ₹24.78 |
| Divi's Laboratories Limited | 87.8× | 16.5% | ₹96.75 |
| Cohance Lifesciences Limited | 95.02× | 7% | ₹4.68 |
| Laurus Labs Limited | 109.36× | 16.8% | ₹16.45 |
| This issue | 52× | 9.48% | ₹19 |
derived: cut-off price Rs988 / stated EPS Rs19 (FY2026 (year ended March 31, 2026) diluted EPS, restated consolidated, per Ind AS 33). Peer figures are as printed in the prospectus — they date from its filing, not today. A multiple is one lens, not a verdict.
Terms of the issue
The mechanics of what is being sold. Held for every issue we track.
Not here yet
The anchor-investor allocation — which institutions were allotted shares before bidding opened — is still to be read out of its document.